Targeted therapy plus radiation for EGFR-positive lung cancer with pleural effusion
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding radiation therapy to the targeted drug furmonertinib can better control advanced lung cancer that has spread to the lining around the lungs (pleural effusion). The main goal is to improve tumor response and possibly reduce future fluid build-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced lung adenocarcinoma (a type of non-small cell lung cancer) that has spread to no more than 3 organs.
- Your cancer has an EGFR mutation (exon 19 deletion or exon 21 L858R).
- You have not had any previous treatment for advanced cancer and have not had chest radiation before.
- You have fluid around your lungs (pleural effusion) that contains cancer cells or shows clear signs of spread on a scan.
- After about 8–10 weeks of taking the study drug (furmonertinib), the fluid is well controlled (minimal or gone) and your tumor is not growing.
- You are generally well enough to carry out daily activities (ECOG 0-2) and your organ and blood counts are within acceptable levels.
- If you have brain metastases, you must not have symptoms from them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a targeted drug (furmonertinib) combined with other treatments before surgery for lung cancer with an EGFR mutation. The goal is to shrink the tumor and make surgery more effective.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
This trial tests whether a targeted pill (furmonertinib) combined with local treatments like radiation or heat/cold to destroy the tumor can help people with early-stage lung cancer that has specific genetic changes (EGFR mutations). It aims to control the cancer without surgery.
This study tests two doses of furmonertinib (a targeted pill) combined with chemotherapy for people with a specific EGFR gene change in lung cancer that has spread to the brain. It aims to see if the higher dose works better while keeping side effects manageable.
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
This trial tests whether furmonertinib, an oral targeted medicine, can improve outcomes after your lung tumor has been completely removed. It also checks for side effects and compares results against placebo in people with specific EGFR gene mutations.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.